Negative in Ames, human lymphocyte chromosome aberration and in vivo micronucleus assays
“Tenapanor was negative in the Ames test, the in vitro mammalian chromosome aberration assay in human peripheral blood lymphocytes, and the in vivo micronucleus assay in mice following oral and IV administration in rats.”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗
Carcinogenicity
2-year rat and 6-month Tg rasH2 mouse: not tumorigenic
“Tenapanor was not tumorigenic in 2-year rat and 6- month Tg rasH2 mouse carcinogenicity bioassays.”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗
Reproductive & developmental
No fertility effects (male rat, female mouse); rat EFD doses of 10 and 30 mg/kg/day not tolerated by dams
“There were no tenapanor-related effects on female or male fertility at doses up to 50 mg/kg/day in female mice and up to 10 mg/kg/day in male rats. In an embryofetal developmental study in rats, tenapanor was administered orally at dose levels of 1, 10 and 30 mg/kg/day from Gestation Days 6 through 17. Dose levels of 10 and 30 mg/kg/day were not tolerated”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗
Safety pharmacology
16.1% hERG inhibition at 10 µM; no cardiovascular/ECG effects in telemetered dogs up to 1000 mg/kg
“Tenapanor showed a slight inhibition (16.1%) of hERG current (IKr) at a concentration 10µM (highest concentration tested) in an in vitro assay in HEK293 cells. However, oral administration of tenapanor to conscious telemetered male beagle dogs at doses up to 1000 mg/kg had no effect on cardiac and circulatory functions”
✓ VerifiedFDA multi-discipline review, p. 32Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative